Clinical trials
catalyst calendar across sponsors →Studies where EPRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 8 tracked-famous managers (Balyasny Asset Management L.P., Point72 Asset Management, L.P., CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, +3 more) · FINRA short interest 13.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).NCT05608681Dose Escalation- Incidence of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: EP-104GI · Other: Matching vehicle control | Eosinophilic Esophagitis | 117 | Dec 2026 | ≤ 134 d | 2026-03-19 |
| Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the KneeNCT04120402results2024-06-25Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain SubscaleRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EP-104IAR 25 mg, Vehicle | Osteoarthritis, Knee | 318 | 2023-05-17actual | — | 2024-06-25 |
| Safety Study of a Long-Acting Injectable Steroid to Treat Knee OsteoarthritisNCT02609126Peak Plasma Concentration (Cmax) of fluticasone propionateRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EP-104IAR, Vehicle | Osteoarthritis, Knee | 32 | 2017-12-28actual | — | 2021-09-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19